Severe pulmonary arterial hypertension (PAH) is rarely observed as initial manifestation of systemic lupus erythematosus (SLE). Lupus myocarditis may rarely be initial presentation as a fatal complication of SLE, which mainly involved with the left ventricle. Here, we present a case of an incident PAH woman who had a delivery history 4 months previously. During hospitalization, she suffered from extensive myocardial damage, refractory ventricular tachycardia, and cardiogenic shock. Ultimately, she was diagnosed with SLE, fulminant lupus myocarditis, and PAH associated with connective tissue disease. After a large dose of methylprednisolone and PAH target therapy treatment, she recovered successfully and got a good result. To the best of our knowledge, this is the first case report of PAH and fulminant lupus myocarditis as initial manifestation of SLE in a previously healthy postpartum woman. This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. 
introduction
Pulmonary arterial hypertension (PAH) is one of the frequently observed complications of systemic lupus erythematosus (SLE) which remodeling of the small pulmonary arteries leads to a progressive increase in pulmonary vascular resistance (PVR) and right heart failure. [1] However, severe PAH is rarely observed as initial manifestation of SLE. According to recent data, the clinical detection of SLE myocarditis ranges from 3% to 15% although its frequency in autopsy studies is higher, suggesting subclinical presentation of the disease. [2] However, clinical symptoms of heart failure are unusual, occurring in only 5%-7% of patients. [3] Lupus myocarditis may rarely be initial presentation as a fatal complication of SLE. After a careful review of the published literature, we believe that this is the first case of PAH and fulminant lupus myocarditis as initial manifestation of SLE. Furthermore, myocarditis predominantly involved right ventricle (RV) rather than the left ventricle in this case.
case report
A 26-year-old prime previously healthy woman developed exertional dyspnea without dizziness, syncope, or chest pain after 4 months of full-term pregnancy. Her pregnancy and puerperium all were normal, and her child was healthy. She went to local hospital, and echocardiogram revealed a dilated RV with a pulmonary arterial systolic pressure (PASP) of 60 mmHg and mild tricuspid regurgitation (TR). She was referred to Shanghai Pulmonary Hospital for the further diagnosis and treatment.
On admission, her temperature was 37.2°C, pulse was 122 beats per min, blood pressure (BP) was 104/70 mmHg, respiration rate was 20 breaths per min, and oxygen saturation was 96.2% on room air. Auscultation revealed loud P2 and a Grade II systolic murmur at the tricuspid area. Legs were mildly edematous. Laboratory findings were N-terminal-pro-brain natriuretic peptide (NT-proBNP) -3473 pg/ml (normal range: 0-125 pg/ml), troponin I (TnI) -0.1900 ug/L (normal range: 0-0.1 ug/L), and erythrocyte sedimentation rate -42 mm/h (normal range: 0-20 mm/h). Arterial blood gas analysis showed a pH: 7.43, PaO 2 : 84 mmHg, PaCO 2 : 25.9 mmHg, and SpO 2 : 96.2%. We primarily diagnosed her with PAH and right heart failure with WHO-FC III. She was treated with dobutamine and prostanoids (iloprost 10 ug q4h) inhalation. The patient's clinical status was slightly improved during treatment.
On the 3 rd day of admission, the patient felt palpitation without chest pain, ECG showed sinus tachycardia, ventricular premature beat and ST-segment elevation in III, avF, V1-V4 lead [ Figure 1b ]. Blood test showed high level of the cardiac marker with creatine kinase -MB 34 U/L and TnI 2.8500 ug/l. NT-proBNP increased significantly to 6432 pg/ml. Meanwhile, her serological findings were positive for SSA and SSB. Considering the patient was young woman without coronary artery disease history, ECG showed extensive myocardial damage, and connective tissue disease (CTD) marker was positive, leading to think as fulminant myocarditis instead of acute myocardial infarction, highly suspected CTD-PAH. The patient was given methylprednisolone and large dose of Vitamin C therapy. Repeated ECG showed persistent ST-segment elevation. Six hours later, the patient developed episode of Stokes-Adams syndrome with abruptly decrease in BP and SpO 2 . ECG showed multifocal premature ventricular contraction and ventricular tachycardia (VT) [ Figure 1c ], and echocardiography showed right heart enlargement, severe TR, and TAPSE 0.9 cm [ Figure 2b ]. We repeatedly gave her cardiopulmonary resuscitation and electric defibrillation eight times together with lidocaine, large dosage of methylprednisolone (total dosage 240 mg), dobutamine, dopamine, adrenaline, and norepinephrine. The patient was resuscitated and his consciousness level gradually restored. Since the next morning, VT no longer occurred. Later, ds-DNA level was reported 37.32 IU/ml (normal range: 0-7.0 IU/ml). Antinuclear antibodies titer was positive and antiphospholipid antibody antibodies were negative. The patient was diagnosed with SLE according to the American College of Rheumatology criteria. Methylprednisolone 1-2 mg/kg day to maintain the 1-2 weeks and hydroxychloroquine 0.1 bid po were initiated for lupus myocarditis. Ambrisentan with sildenafil was added to decrease PVR as she could not inhale iloprost. ECG showed ST-segment gradually declined to baseline [ Figure 1d ], and cardiac enzyme and NT-proBNP gradually decreased to normal range. After 27-day hospitalization, her right heart catheterization showed right atrial pressure 7/2/4mmHg, pulmonal arterial pressure 40/19/28 mmHg, pulmonary capillary wedge pressure 6/3/4 mmHg, cardiac output 4.57 L/min, cardiac index 3.17 L/min/m 2 , PVR 5.25 Wood U, and negative pulmonary vasoreactive test. Echocardiogram showed mild dilated right heart with a PASP of 42 mmHg, mild TR, and TAPSE 2.0 cm [ Figure 2c ].
After 1 month of discharge, the patient follow-up examination revealed WHO-FC II, 6-min walk distance 420 m, NT-proBNP 26 pg/ml, echocardiography showed mild dilated right heart with a PASP of 42 mmHg, mild TR, and TAPSE 2.0 cm.
discussion
We presented a rare case of SLE who presented with PAH and fulminant myocarditis, right heart failure, and life-threatening ventricular arrhythmias (VT/ventricular fibrillation). To our PAH is a devastating disease in which remodeling of the small pulmonary arteries leads to a progressive increase in PVR and right heart failure. [1] In China, the proportion of CTD-PAH is about 19% including SLE 51.1%, pSS 15.6%, and SSC 15.5% (unpublished data). However, severe PAH is rarely observed as the initial manifestation of SLE.
Myocarditis is one of the most possible forms of cardiac involvement in SLE. Its clinical presentation ranges from asymptomatic patients with self-limited disease to fulminant heart failure that can lead to death. Most myocarditis in SLE is asymptomatic but may be manifest with fever, dyspnea, palpitation, and nonexertional chest pain. [4] Subclinical cardiac involvement in SLE is seen by the prevalence of myocarditis from necropsy studies to be 40%-70%. However, symptomatic myocarditis had been reported in only 5%-10% of cases. [5] The presentation of myocarditis depends on the degree of cardiac dysfunction ranging from mild dyspnea or chest pain, arrhythmias, heart failure, and cardiogenic shock to sudden death. [6] Lupus myocarditis may rarely be initial presentation as a fatal complication of SLE. Lupus myocarditis needs urgent clinical attention because of the likely progression to arrhythmias, conduction disturbances and heart block, dilated cardiomyopathy, and heart failure. The prevalence of arrhythmias and conduction system disorders in SLE is currently unknown due to the small number of studies in the literature. Malignant ventricular arrhythmias are rarely reported. [7] In our case, the PAH patient presented with elevated ST segment with cardiac injury and malignant arrhythmias on the 2 nd day of admission. As she is a young woman without chest pain, D-dimer nearly normal, abnormal CTD marker, we considered myocarditis rather than acute myocardial infarction. Subsequent rheumatic and immunology examination indicated as lupus myocarditis.
Symptomatic left ventricular dysfunction is the most common clinical presentation of lupus cardiomyopathy and is potentially life-threatening which acute onset of a marked reduction of the left ventricular ejection fraction. Echocardiographic findings in lupus myocarditis mainly include decreased ejection fraction and increased chamber size. Interestingly, in our case, SLE myocarditis mainly involved right heart as echo showed her right heart size, and function was significantly abnormal (TAPSE low and RV dilation) while her left ventricle function was always normal. A systematic MEDLINE/PubMed from 1993 to 2014 only identified one case of myopericarditis with predominantly RV involvement as the initial manifestation of SLE.
[8] The goal of treatment for acute lupus myocarditis is to manage heart failure, arrhythmias, and SLE activity. In our case, lupus myocarditis predominantly involved RV which mainly presented as PAH and right heart failure, we used large dose of intravenous methylprednisolone, PAH target therapy (sildenafil and ambrisentan), and positive inotropic drugs to help her recover.
This case reminds us, the clinician should pay more attention to postpartum PAH, especially screening of CTD. Identifying the cause is critical as it dictates therapy. Early diagnosis and a combination treatment for the right heart failure, immunosuppression, and arrhythmias may result in a favorable outcome. 
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